The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...